PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research report released on Monday morning,Benzinga reports. They currently have a $14.00 target price on the stock.

Separately, Craig Hallum assumed coverage on shares of PolyPid in a report on Monday, November 4th. They issued a “buy” rating and a $10.00 price target on the stock.

PolyPid Stock Down 6.9 %

Shares of NASDAQ PYPD opened at $2.43 on Monday. The firm’s fifty day moving average is $3.32 and its 200 day moving average is $3.59. PolyPid has a 52 week low of $2.37 and a 52 week high of $9.20. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 1.17. The company has a market cap of $11.66 million, a price-to-earnings ratio of -0.31 and a beta of 1.33.

Institutional Investors Weigh In On PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC bought a new stake in shares of PolyPid Ltd. (NASDAQ:PYPD) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned approximately 2.89% of PolyPid as of its most recent SEC filing. Institutional investors and hedge funds own 26.47% of the company’s stock.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.